Directly to content
  1. Publishing |
  2. Search |
  3. Browse |
  4. Recent items rss |
  5. Open Access |
  6. Jur. Issues |
  7. DeutschClear Cookie - decide language by browser settings

CD133 expression in cancer cells predicts poor prognosis of non-mucin producing intrahepatic cholangiocarcinoma

Cai, Xiaobo ; Li, Jun ; Yuan, Xiaodong ; Xiao, Jingbo ; Dooley, Steven ; Wan, Xinjian ; Weng, Honglei ; Lu, Lungen

In: Journal of Translational Medicine, 16 (2018), Nr. 50. pp. 1-7. ISSN 1479-5876

[img]
Preview
PDF, English
Download (1MB) | Lizenz: Creative Commons LizenzvertragCD133 expression in cancer cells predicts poor prognosis of non-mucin producing intrahepatic cholangiocarcinoma by Cai, Xiaobo ; Li, Jun ; Yuan, Xiaodong ; Xiao, Jingbo ; Dooley, Steven ; Wan, Xinjian ; Weng, Honglei ; Lu, Lungen underlies the terms of Creative Commons Attribution 4.0

Citation of documents: Please do not cite the URL that is displayed in your browser location input, instead use the DOI, URN or the persistent URL below, as we can guarantee their long-time accessibility.

Abstract

Background; CD133 is a marker of stem cells as well cancer stem cells. This study investigated the association between CD133 expression in cancer cells and the clinical outcome of non-mucin producing intrahepatic cholangiocarcinoma (ICC).

Methods: Fifty-seven non-mucin producing ICC patients were enrolled in this study. Immunohistochemistry (IHC) and immunofluorescence staining for CD133 as well as other cancer-associated proteins, including cytokeratin 19, TGF-β1, p-Smad2 and epithelial–mesenchymal transition (EMT) markers S100A4, E-Cadherin and Vimentin were analyzed.

Results: IHC staining showed that tumor cells in 52.6% of patients expressed CD133. The CD133+ patients had significantly higher metastasis rate than those without CD133+ tumor cells (36.7% vs. 10.1%, p = 0.03). The CD133+ patients had shorter overall and disease-free survival time as compared to the CD133− patients. Furthermore, 90.9% of CD133+ patients developed cancer recurrence, as compared to 64.3% of CD133− patients (p = 0.02). As compared to CD133− patients, tumor cells in CD133+ patients demonstrated high levels of TGF-β/p-Smad2 as well as EMT-like alteration, characterized by loss of E-Cadherin and expression of Vimentin and S100A4.

Conclusions: CD133 expression in ICC tumor cells indicates poor prognosis of the disease and might be associated with TGF-β related EMT alterations.

Item Type: Article
Journal or Publication Title: Journal of Translational Medicine
Volume: 16
Number: 50
Publisher: BioMed Central
Place of Publication: London
Date Deposited: 27 Apr 2018 09:54
Date: 2018
ISSN: 1479-5876
Page Range: pp. 1-7
Faculties / Institutes: Medizinische Fakultät Mannheim > Medizinische Klinik - Lehrstuhl für Innere Medizin II
Subjects: 610 Medical sciences Medicine
About | FAQ | Contact | Imprint |
OA-LogoDINI certificate 2013Logo der Open-Archives-Initiative